Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 6:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 571 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Allergic Disease Clear all
Completed Phase 4 Interventional Results available

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

NCT00621959
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
levocetirizine dihydrochloride, placebo
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Jun 7, 2026, 6:15 AM EDT
Completed Phase 4 Interventional Results available

The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis

NCT02696850
View directory record Official record
Conditions
Rhinosinusitis, Chronic Eosinophilic Rhinosinusitis, Allergic Rhinosinusitis
Interventions
Budesonide, Saline alone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 2, 2019 · Synced Jun 7, 2026, 6:15 AM EDT
Completed Phase 4 Interventional Results available

Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis

NCT01154153
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial and/or Seasonal
Interventions
Placebo nasal spray, Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ), Claritin® Syrup
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 12 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
Cypress, California • Stockbridge, Georgia • North Dartmouth, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Jun 7, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies

NCT04622345
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
VSJ-110, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jun 7, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis

NCT01033825
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Ciclesonide HFA Nasal Aerosol 320 mcg, Ciclesonide HFA Nasal Aerosol 160 mcg, HFA Nasal Aerosol placebo, Ciclesonide Aqueous Nasal Spray 200 mcg, AQ Nasal Spray Placebo, Placebo plus Dexamethasone HFA, Placebo AQ plus Dexamethasone 6 mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Stockbridge, Georgia • North Dartmouth, Massachusetts • Minneappolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2012 · Synced Jun 7, 2026, 6:15 AM EDT
Completed No phase listed Observational

Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections

NCT00405899
View directory record Official record
Conditions
Allergy, Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis
Interventions
Not listed
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2010 · Synced Jun 7, 2026, 6:15 AM EDT
Completed Phase 1 Interventional

A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL

NCT02557633
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Grass MATA MPL 10200, Grass MATA MPL 18200, Placebo
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Neptune City, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jun 7, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)

NCT01133626
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Placebo Nasal Aerosol, Prednisone capsules, Placebo Prednisone Capsules, Beclomethasone dipropionate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years to 45 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
North Dartmouth, Massachusetts • New Braunfels, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Jun 7, 2026, 6:15 AM EDT
Completed Phase 3 Interventional

A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy

NCT06602739
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
REGN5713, REGN5715, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jun 7, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of a Eye Drop for Eye Allergy

NCT00889330
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
alcaftadine, Placebo
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
2
States / cities
Fairfield, Ohio • Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Jun 7, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

NCT04991935
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
CC-93538
Drug
Lead sponsor
Celgene
Industry
Eligibility
12 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
81
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jun 7, 2026, 6:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis

NCT00424398
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
Bepreve, Placebo, Bepotastine Besilate
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
10 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Jun 7, 2026, 6:15 AM EDT
Completed Phase 1Phase 2 Interventional

Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis

NCT03018275
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Roseomonas mucosa
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Jun 7, 2026, 6:15 AM EDT
Completed Phase 4 Interventional

Study of Bronchodilation Effects of Cetirizine

NCT01781507
View directory record Official record
Conditions
Allergic Rhinitis, Asthma
Interventions
Cetirizine, Placebo
Drug
Lead sponsor
California Allergy and Asthma Medical Group, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2013 · Synced Jun 7, 2026, 6:15 AM EDT
Completed Phase 2 Interventional

Clinical Evaluation of Bacitracin

NCT00132600
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
bacitracin (allergen)
Drug
Lead sponsor
Mekos Laboratories AS
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 18, 2005 · Synced Jun 7, 2026, 6:15 AM EDT
Completed No phase listed Observational Results available

Home Usability of a Nasal Lavage System in Children

NCT01129765
View directory record Official record
Conditions
Nasal Congestion, Respiratory Tract Infection, Sinusitis, Allergic Rhinitis
Interventions
Use of an automatic nasal irrigator/aspirator
Device
Lead sponsor
Aardvark Medical Company
Industry
Eligibility
Up to 5 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Vienna, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 2, 2010 · Synced Jun 7, 2026, 6:15 AM EDT
Completed No phase listed Observational

Validation of Laser Doppler Flowmetry to Identify Allergic Rhinitis Patients With Pharmacogenetic Alterations in Histamine Metabolism

NCT00362999
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
7 Years to 18 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2024
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jun 7, 2026, 6:15 AM EDT
Completed Phase 3 Interventional

An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis

NCT01561521
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AKF-1
Drug
Lead sponsor
Akorn, Inc.
Industry
Eligibility
10 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Jun 7, 2026, 6:15 AM EDT
Terminated Phase 1 Interventional

A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis

NCT01122914
View directory record Official record
Conditions
Anakinra, Kineret, Atopic Dermatitis, Eczema, Allergic Disease
Interventions
Anakinra
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jun 7, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis

NCT02978183
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
ST266, Saline (0.9% NaCl)
Biological · Drug
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Andover, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Jun 7, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

To Study GSP 301 in Patients With Seasonal Allergic Rhinitis

NCT02318303
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
GSP 301-1 NS (QD), GSP 301-2 NS (BID), GSP 301 Placebo NS, Olopatadine HCl-1 NS (QD), Olopatadine HCl-2 NS (BID), Mometasone Furoate-1 NS (QD), Mometasone Furoate-2 NS (BID)
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
12 Years and older
Enrollment
1,111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Jun 7, 2026, 6:15 AM EDT
Terminated Phase 3 Interventional Results available

Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)

NCT05545072
View directory record Official record
Conditions
Allergic Fungal Rhinosinusitis
Interventions
Dupilumab, Placebo, Intranasal Corticosteroid Sprays (INCS)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Jun 7, 2026, 6:15 AM EDT
Completed Early Phase 1 Interventional

Xolair Treatment for Milk Allergic Children

NCT00968110
View directory record Official record
Conditions
Milk Allergy
Interventions
omalizumab
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
4 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Jun 7, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis

NCT00720382
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
0.15% azelastine hydrochloride, Mometasone furoate
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
59
States / cities
Oxford, Alabama • Fountain Valley, California • Huntington Beach, California + 50 more
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Jun 7, 2026, 6:15 AM EDT